Denise Neves Gameiro, Author at Labiotech.eu - Page 19 of 24

About

Journalist intern. Studied Bioengineering in Porto and was a lab rat in Sweden. Enjoying Berlin and the company of Labiotech’s resident plants.

Articles by Denise Neves Gameiro

metabomed ms ventures series a pfizer

News and Trends 5 Apr 2016

Israeli Cancer Startup catches Investment from 3 major Big Pharma

Metabomed is developing new highly-selective drugs that target cancer metabolism – and it has now raised €15.8M in a series A round and gotten a new CEO from Merck’s ranks. Metabomed was co-founded by MS Ventures (the VC arm of Merck KGaA) and leading researchers in the field of cancer metabolism and computational biology back in 2014. I must […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

anergis allergy birch allert cop

News and Trends 4 Apr 2016

Allergy Immunotherapy from Switzerland gets several Million in funding

Anergis (Switzerland) has gotten €4.5M from investors and is planning a phase IIb trial for ATIBAR, its leading candidate to treat Tree allergies. Anergis is developing ultra-fast immunotherapies for allergies, which could be an interesting alternative to current treatments, known as ‘desensitization’ or conventional Allergy Immunotherapy (AIT). This process of inducing tolerance to the allergen requires 3-5 […]

April 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

bioart joana ricou multitudes microbiome

News and Trends 2 Apr 2016

BioArt: Joana Ricou shows the Beautiful Similarities of the Microbiome

Joana Ricou has been dwelling on the frontier of biology and science since she enrolled an Art&Biology programme at Carnegie Mellon (US). Her BioArt works explore the perception of our bodies and the multitudes inside each of us – with a rather scientific approach. We have covered a small part of Ricou’s on our event […]

April 2, 2016 - 4 minutesmins - By Denise Neves Gameiro

biomoti oncojan physiomics virtual tumor

News and Trends 1 Apr 2016

When Nanoparticles meet Virtual Tumours to build Oncology Platform

BioMoti is enhancing cancer treatments via drug delivery innovation and it was one of the companies we visited during Labiotech Tour UK. Its Oncojan platform has caught the eye of Physiomics, a computational system biology Biotech listed on the London Stock Exchange. Oxford-based Physiomics develops computational models of cancer, allowing to simulate the effect of […]

April 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

genfit primary billiary cholangitis elafibranor

News and Trends 31 Mar 2016

Beyond NASH: Genfit jumps into another Critical Liver Condition

Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease – Primary Biliary Cholangitis (PBC), a rare condition with high unmet medical needs. Genfit from Lille (France) has been in the spotlight because of its phase III candidate for NASH – something we discussed with its CEO, Jean-François Mouney. Apparently, all the […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

affimed afmd 2015 results immuno oncology

News and Trends 31 Mar 2016

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology. Affimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

immunocore uveal melanoma trial imcgp100

News and Trends 31 Mar 2016

Money Magnet Immunocore kicks off Trial for Eye Melanoma

Immunocore (UK) has enrolled its first patient for a phase I trial that will test its ImmTAC as a standalone therapy for uveal melanoma, the most common eye cancer. Immunocore is famous for having raised the biggest European Private round ever (€300M), and so it’s no wonder that if often makes our tops here at […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

epigenomics china biochain lung cancer

News and Trends 30 Mar 2016

German Biotech targets China for Lung Cancer Liquid Biopsies

Epigenomics (Germany and US) has closed a deal to develop and commercialize a new blood-based lung cancer diagnostic in China, one of its highest performing markets. There are many biotech efforts to find treatments for cancer, but a separate strategy to lower cancer mortality is to improve diagnosis – so that people can be treated when […]

March 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

gadeta cancer immuno leukemia tumours

News and Trends 30 Mar 2016

Dutch Startup gets €7M for New Cancer Immunotherapy Platform

Gadeta has raised €7M in a series A round, which will fuel the clinical development of its novel TCR platform, starting with a leukemia cell therapy trial. Gadeta is a spin-out of immuno-oncology research at the University Medical Center Utrecht (UMC Utrecht). It was founded in 2015 by the researchers and Utrecht Holdings, the technology transfer […]

March 30, 2016 - 2 minutesmins - By Denise Neves Gameiro

gairdner awards biomedical research crispr hiv

News and Trends 29 Mar 2016

The CRISPR ‘Crew’ continues World Tour of Scientific Prize Collection

CRISPR remains in the spotlight as the scientific discovery of the century. A long list of ‘inventors’ have been awarded the Canada Gairdner Awards, which recognise innovative biomedical research. The Gairdner Foundation (Canada) has chosen its 2016 picks for the ‘world’s best and brightest’ research in the biomedical sciences. The lucky winners this year work […]

March 29, 2016 - 4 minutesmins - By Denise Neves Gameiro

bone therapeutics bothex allob preob

News and Trends 29 Mar 2016

Belgian Cell Therapy Biotech Excelling in Trials to Treat Severe Osteoporosis

Bone Therapeutics (Belgium) has released its financial results for 2015, which show a solid cash position and promising results in treating Bone conditions in ongoing clinical trials. This Belgian Biotech is developing cell therapies to treat a bone diseases like osteoporosis with considerable success so far – and 2015 was a year with plenty of important milestones. These […]

March 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

tevas asthma reslizumab cinqair

News and Trends 25 Mar 2016

Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma

Teva (Israel) can now commercialize their intravenous drug (Cinqair) in the US, which will help adults with severe asthma. Based near Tel Aviv, Teva is the largest producer of generics, but it is also conducting its own biotech research. These include collaborations with Active Biotech (Sweden) for treatment of Huntington’s disease, and Heptares Therapeutics […]

March 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT